RECRUITING

SPECT/CT Imaging for Dosimetry in 177Lu-PSMA-617 (Pluvicto) Therapy

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study is being performed to establish the association between absorbed dose to tumor and response and absorbed dose to normal organs and toxicity following Lu177-PSMA radioligand therapy

Official Title

SPECT/CT Imaging for Dosimetry in 177Lu-PSMA-617 (Pluvicto) Therapy

Quick Facts

Study Start:2025-01-23
Study Completion:2031-01-23
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT07096999

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:MALE
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * \* 177Lu-617 PSMA treatment scheduled for mCRPC
  2. * Clinically stable as determined by the nuclear medicine clinicians
  3. * Male
  4. * ≥ 18 years of age
  5. * Willing and able to provide informed consent
  1. * Patients who are unable to lie flat on the imaging systems long enough to permit imaging protocols to be performed

Contacts and Locations

Principal Investigator

Yuni K Dewaraja
PRINCIPAL_INVESTIGATOR
University of Michigan Rogel Cancer Center

Study Locations (Sites)

University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, 48109
United States

Collaborators and Investigators

Sponsor: University of Michigan Rogel Cancer Center

  • Yuni K Dewaraja, PRINCIPAL_INVESTIGATOR, University of Michigan Rogel Cancer Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-01-23
Study Completion Date2031-01-23

Study Record Updates

Study Start Date2025-01-23
Study Completion Date2031-01-23

Terms related to this study

Keywords Provided by Researchers

  • Prostate Cancer
  • 177Lu
  • PSMA
  • mCRPC
  • Radioligand Therapy

Additional Relevant MeSH Terms

  • Metastatic Castration-Resistant Prostate Carcinoma